Clinical comparison on the second generation of cephalosporins and mezlocillin sodium with sulbactam sodium in treating the elder community acquired pneumonia

Abstract

Objective To compare the clinical efficacy of second generation of cephalosporins and mezlocillin sodium with sulbactam sodium on the elder community acquired pneumonia(CAP). Methods Eighty cases of the elder community acquired pneumonia(CAP), in accordance with the random number table, were divided into research group(n=40) and control group(n=40). The control group were given the second generation of cephalosporins, namely cefuroxime sodium, and the research group were given mezlocillin sodium and sulbactam sodium. The recovery time, therapy costs were analyzed. Results The total effective rate of research group(95%) was much higher than that of the control group(90%), but there was no significant difference between the two groups(P>0.05); the recovery time of clinical signs and therapy costs in the research group were both shorter and less than that in the control group, and the differences were significant(P<0.05). Conclusions The clinical effect of second generation of cephalosporins and the mezlocillin sodium and sulbactam sodium the elder community acquired pneumonia(CAP) is good, but patients treated with mezlocillin sodium and sulbactam sodium recover fast and cost less, which is worth of clinical promotiom. Key words: Second generation of cephalosporins; Mezlocillin sodium and sulbactam sodium; Community acquired pneumonia; Clinical effect